vs
Forian Inc.(FORA)与礼来(RNA)财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是Forian Inc.的1.6倍($12.5M vs $8.0M),Forian Inc.净利率更高(-22.9% vs -1398.3%,领先1375.5%),礼来同比增速更快(434.0% vs 37.0%),过去两年礼来的营收复合增速更高(138.5% vs 27.8%)
Forian Inc是一家专注于医疗健康领域的数据分析与技术服务商,提供SaaS模式的真实世界证据解决方案、临床决策支持工具及运营优化服务,客户覆盖生物制药企业、医疗机构及生命科学领域相关机构,助力提升诊疗效率、推动医学研究进展。
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业,在18个国家设有办事处,产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立,品牌名即取自创始人姓名。
FORA vs RNA — 直观对比
营收规模更大
RNA
是对方的1.6倍
$8.0M
营收增速更快
RNA
高出397.0%
37.0%
净利率更高
FORA
高出1375.5%
-1398.3%
两年增速更快
RNA
近两年复合增速
27.8%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $8.0M | $12.5M |
| 净利润 | $-1.8M | $-174.4M |
| 毛利率 | 49.2% | — |
| 营业利润率 | -24.4% | -1513.5% |
| 净利率 | -22.9% | -1398.3% |
| 营收同比 | 37.0% | 434.0% |
| 净利润同比 | -1012.2% | -117.0% |
| 每股收益(稀释后) | $-0.06 | $-1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
FORA
RNA
| Q4 25 | $8.0M | — | ||
| Q3 25 | $7.8M | $12.5M | ||
| Q2 25 | $7.5M | $3.8M | ||
| Q1 25 | $7.1M | $1.6M | ||
| Q4 24 | $5.8M | $3.0M | ||
| Q3 24 | $4.7M | $2.3M | ||
| Q2 24 | $4.8M | $2.0M | ||
| Q1 24 | $4.9M | $3.5M |
净利润
FORA
RNA
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-151.2K | $-174.4M | ||
| Q2 25 | $224.8K | $-157.3M | ||
| Q1 25 | $-1.1M | $-115.8M | ||
| Q4 24 | $199.7K | $-102.3M | ||
| Q3 24 | $-204.9K | $-80.4M | ||
| Q2 24 | $-2.6M | $-70.8M | ||
| Q1 24 | $-1.2M | $-68.9M |
毛利率
FORA
RNA
| Q4 25 | 49.2% | — | ||
| Q3 25 | 51.6% | — | ||
| Q2 25 | 56.8% | — | ||
| Q1 25 | 55.6% | — | ||
| Q4 24 | 58.3% | — | ||
| Q3 24 | 70.1% | — | ||
| Q2 24 | 62.2% | — | ||
| Q1 24 | 65.1% | — |
营业利润率
FORA
RNA
| Q4 25 | -24.4% | — | ||
| Q3 25 | -6.1% | -1513.5% | ||
| Q2 25 | 0.6% | -4448.7% | ||
| Q1 25 | -19.8% | -8360.9% | ||
| Q4 24 | -24.9% | -4069.6% | ||
| Q3 24 | -17.0% | -4200.9% | ||
| Q2 24 | -62.2% | -4040.4% | ||
| Q1 24 | -36.3% | -2178.6% |
净利率
FORA
RNA
| Q4 25 | -22.9% | — | ||
| Q3 25 | -1.9% | -1398.3% | ||
| Q2 25 | 3.0% | -4089.3% | ||
| Q1 25 | -16.0% | -7360.0% | ||
| Q4 24 | 3.4% | -3439.5% | ||
| Q3 24 | -4.4% | -3441.7% | ||
| Q2 24 | -53.4% | -3461.8% | ||
| Q1 24 | -24.9% | -1943.4% |
每股收益(稀释后)
FORA
RNA
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.00 | $-1.27 | ||
| Q2 25 | $0.01 | $-1.21 | ||
| Q1 25 | $-0.04 | $-0.90 | ||
| Q4 24 | $0.01 | $-0.80 | ||
| Q3 24 | $-0.01 | $-0.65 | ||
| Q2 24 | $-0.08 | $-0.65 | ||
| Q1 24 | $-0.04 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $31.6M | $350.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $29.8M | $1.9B |
| 总资产 | $44.1M | $2.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
FORA
RNA
| Q4 25 | $31.6M | — | ||
| Q3 25 | $28.2M | $350.2M | ||
| Q2 25 | $35.6M | $243.9M | ||
| Q1 25 | $35.7M | $254.2M | ||
| Q4 24 | $35.1M | $219.9M | ||
| Q3 24 | $49.4M | $370.2M | ||
| Q2 24 | $48.0M | $575.8M | ||
| Q1 24 | $47.4M | $471.4M |
股东权益
FORA
RNA
| Q4 25 | $29.8M | — | ||
| Q3 25 | $31.1M | $1.9B | ||
| Q2 25 | $30.9M | $1.2B | ||
| Q1 25 | $30.0M | $1.3B | ||
| Q4 24 | $30.1M | $1.4B | ||
| Q3 24 | $28.4M | $1.5B | ||
| Q2 24 | $27.2M | $1.2B | ||
| Q1 24 | $28.1M | $830.9M |
总资产
FORA
RNA
| Q4 25 | $44.1M | — | ||
| Q3 25 | $41.3M | $2.1B | ||
| Q2 25 | $48.5M | $1.4B | ||
| Q1 25 | $48.6M | $1.5B | ||
| Q4 24 | $47.2M | $1.6B | ||
| Q3 24 | $57.5M | $1.6B | ||
| Q2 24 | $58.4M | $1.3B | ||
| Q1 24 | $57.5M | $951.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $3.2M | $-156.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-156.9M |
| 自由现金流率自由现金流/营收 | — | -1257.6% |
| 资本支出强度资本支出/营收 | — | 5.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-592.3M |
8季度趋势,按日历期对齐
经营现金流
FORA
RNA
| Q4 25 | $3.2M | — | ||
| Q3 25 | $-439.7K | $-156.2M | ||
| Q2 25 | $-344.5K | $-199.7M | ||
| Q1 25 | $448.2K | $-124.8M | ||
| Q4 24 | $1.7M | $-99.9M | ||
| Q3 24 | $764.1K | $-65.6M | ||
| Q2 24 | $-23.1K | $-65.0M | ||
| Q1 24 | $-2.2M | $-70.4M |
自由现金流
FORA
RNA
| Q4 25 | — | — | ||
| Q3 25 | — | $-156.9M | ||
| Q2 25 | — | $-203.0M | ||
| Q1 25 | — | $-128.6M | ||
| Q4 24 | — | $-103.8M | ||
| Q3 24 | — | $-67.3M | ||
| Q2 24 | — | $-65.5M | ||
| Q1 24 | — | $-71.3M |
自由现金流率
FORA
RNA
| Q4 25 | — | — | ||
| Q3 25 | — | -1257.6% | ||
| Q2 25 | — | -5277.1% | ||
| Q1 25 | — | -8174.3% | ||
| Q4 24 | — | -3491.0% | ||
| Q3 24 | — | -2881.8% | ||
| Q2 24 | — | -3204.6% | ||
| Q1 24 | — | -2012.3% |
资本支出强度
FORA
RNA
| Q4 25 | — | — | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 86.9% | ||
| Q1 25 | — | 238.6% | ||
| Q4 24 | 0.0% | 131.7% | ||
| Q3 24 | 0.0% | 72.9% | ||
| Q2 24 | 0.0% | 26.0% | ||
| Q1 24 | 0.0% | 25.8% |
现金转化率
FORA
RNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -1.53× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 8.76× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORA
| Financial Services Revenues | $7.3M | 92% |
| Other | $669.0K | 8% |
RNA
暂无分部数据